Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 19/20 | 0.53 |
| ▸ | EPX | P11678 | 2/20 | 0.53 |
| ▸ | TPO | P07202 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.34 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.34 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.34 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22406585 | 0.89 | MPO (0.59) | MPOEPXTPOCYP3A4 | |
| SCHEMBL22406670 | 0.89 | MPO (0.50) | MPOEPXTPOCYP3A4 | |
| SCHEMBL22423896 | 0.85 | MPO (0.72) | MPOEPXTPOCYP3A4 | |
| SCHEMBL19359413 | 0.85 | MPO (0.72) | MPOEPXTPOCYP3A4 | |
| SCHEMBL22423839 | 0.85 | MPO (0.72) | MPOEPXTPOCYP3A4 | |
| SCHEMBL22406482 | 0.80 | MPO (0.55) | MPOEPXTPOCYP3A4 | |
| SCHEMBL22406647 | 0.80 | MPO (0.54) | MPOEPXTPOCYP3A4 | |
| SCHEMBL22406409 | 0.80 | MPO (0.55) | MPOEPXTPOCYP3A4 | |
| SCHEMBL22423876 | 0.80 | MPO (0.53) | MPOEPXTPOCYP3A4 | |
| SCHEMBL22423914 | 0.80 | MPO (0.53) | MPOEPXTPOCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11008317-B2 | Triazolopyridine inhibitors of myeloperoxidase and/or EPX | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-05-18 | — | — | US | disclosed |
| US-20200291016-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE AND/OR EPX | BRISTOL MYERS SQUIBB CO (US) | 2020-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200291016-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE AND/OR EPX | EPX, MPO, SERPINB1 | MPO 2/4885EPX 1/4885TPO 31/4885 |
| US-11008317-B2 | Triazolopyridine inhibitors of myeloperoxidase and/or EPX | EPX, MPO, SERPINB1 | MPO 2/4885EPX 1/4885TPO 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.